Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

Inclusion Criteria:

* Age \>= 60 ans
* Poor prognosis AML defined according to the following criteria:1. For first-line AML:intermediate or unfavorable risk according to ELN 2022 2.for Relapsed AML:regardless of the ELN risk group
* ECOG \<= 2
* Patient eligible for intensive chemotherapy
* Who provide their written informed consent
* Liver workup: transaminases \< 3x normal, bilirubin \< 1.5 X normal
* Creatinine clearance \> 60ml/mn
* LVEF \>= 50%.

Exclusion Criteria:

* Patients with FLT3 ITD or TKD mutation
* Patients with tuberculosis
* Patients with documented active infection with COVID 19
* Patients with hereditary fructose intolerance (HFI)
* Uncontrolled infection
* Active or past infection with Hep B, C or HIV+
* Not Affiliated with French social security system or no beneficiary from such system
* Pregnant women or patients who cannot take contraception ( contraceptive pill, abstinence, unauthorised IUD) in case of fertility. A patient who cannot continue contraception for at least 6 months after the last injection of DARATUMUMAB is not eligible for inclusion.
* Breastfeeding women
* Minors
* Adults under guardianship, curatorship or safeguard of justice
* Hypersensitivity to any of the active ingredients or excipients
* Patients with significant cardiovascular pathology including any of the following: myocardial infarction within 6 months prior to study entry, unstabilized coronary artery disease, uncontrolled hypertension, congestive heart failure.
* Patient with disease requiring systemic immunosuppressive therapy (such as high-dose steroids defined as ≥ 10mg prednisone or equivalent per day) within 4 weeks prior to the 1st scheduled dose of study treatment with the exception of dermocorticoids